Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal
DEA withdraws proposed rule to reschedule marijuana from Schedule I to Schedule III, maintaining current federal scheduling.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies, dispensaries, and entities handling marijuana under state law; independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (April 28, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The proposed rule to transfer marijuana from Schedule I to Schedule III is withdrawn, so marijuana remains a Schedule I controlled substance under federal law.
Who it affects
All pharmacies, dispensaries, and entities handling marijuana under state law; independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies.
What you must do
Continue operating under existing Schedule I compliance requirements; no change to current federal restrictions.
Deadline
Immediately upon publication (April 28, 2026).
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- New Maine law increases access to birth control at pharmacies - WGME
- Andrew Jonathan Morgan: Final Debarment Order
- SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Exempt Chemical Preparations Under the Controlled Substances Act